Actio Biosciences launches Phase 1b/2 trial for ultra-rare pediatric epilepsy therapy
The company also confirmed that ABS-1230 has been accepted into the U.S. Food and Drug Administration’s Rare Disease Evidence Principles (RDEP) process
The company also confirmed that ABS-1230 has been accepted into the U.S. Food and Drug Administration’s Rare Disease Evidence Principles (RDEP) process
Subscribe To Our Newsletter & Stay Updated